Who Paid My Doc
Christopher Perkins
Hematology & Oncology Fresno, CA Medical Doctor
NPI 1396820189 CMS profile 108298
6121 N Thesta, Ste 204, Fresno, CA 93710
General payments
$9,930
Research payments
$2,106
Ownership & investment interest
$0
Research they led as principal investigator
$93,275
Through program year 2025, Christopher Perkins of Fresno, CA is reported in the CMS Open Payments database as having received $9,930 across 312 general payments and $2,106 in research payments paid to them. Separately, studies naming them as principal investigator received $93,275 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 74th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $28 | 1 | |
| 2025 | Research | $41 | 1 | |
| 2023 | General | $140 | 4 | |
| 2023 | Research | $724 | 1 | |
| 2022 | General | $1,744 | 67 | |
| 2022 | Research | $1,341 | 1 | |
| 2021 | General | $1,706 | 101 | |
| 2020 | General | $1,502 | 92 | |
| 2019 | General | $4,811 | 47 |
Beside peers
- Christopher Perkins
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Christopher Perkins were reported at $28. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Christopher Perkins | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,811 | $529 | $121–$2,516 | $163 |
| 2020 | $1,502 | $339 | $82–$2,213 | $114 |
| 2021 | $1,706 | $263 | $49–$1,965 | $132 |
| 2022 | $1,744 | $416 | $103–$2,395 | $149 |
| 2023 | $140 | $542 | $125–$2,646 | $160 |
| 2024 | $0 | $692 | $141–$3,008 | $164 |
| 2025 | $28 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
315 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in California
Dennis Slamon
Hematology & Oncology · Los Angeles, CA
Sandra Horning
Hematology & Oncology · Stanford, CA
Mohammadbagher Ziari
Hematology & Oncology · Corona, CA
George Yaghmour
Hematology & Oncology · Los Angeles, CA
Robert Vescio
Hematology & Oncology · West Hollywood, CA
Kevin Kelly
Hematology & Oncology · Los Angeles, CA
Related records
Hematology & Oncology in California
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.